Interestingly, preclinical and clinical evidence demonstrated that BCR-ABL/SRC inhibitors enhance the cytotoxic effects of T-cells and the efficacy of ICBs [9,39,40], suggesting that BCR-ABL/SRC inhibitors not only target the cancer cells but also modulate the tumor immune microenvironment. This evidence concerns the gene ABL1 and neoplasm.